Bausch Health Companies Inc. (BHC) plunged over 10% on January 24, 2026, with the stock price falling to $5.90. The sharp decline follows a period of heightened volatility for the pharmaceutical firm, which underperformed its industry peers significantly during the session.
Shares traded within a day range of $5.86 to $6.24, nearing the lower end of its 52-week range of $4.25 to $8.69.
| Current Price | $5.90 |
| Daily Change | -10.20% 🔴 |
| Day Range | $5.86 – $6.24 |
| 52-Week Range | $4.25 – $8.69 |
The selloff comes on the heels of a nearly 9% drop on Friday, January 23, following news regarding the company's clinical pipeline. While Bausch Health released significant clinical updates, some market analysis reports indicated that the immediate catalyst for the magnitude of the slide remained partially unexplained by a single event, suggesting a broader loss of investor confidence.
With this latest movement, Bausch Health’s stock has declined more than 15.5% over the last month. The company currently holds a market capitalization of approximately C$3.02 billion as it prepares for its upcoming annual financial reporting.
Key Takeaways
- BHC stock dropped over 10% to $5.90, significantly underperforming the specialty drug industry.
- The RED-C Phase 3 clinical program failed to meet its primary efficacy endpoint.
- CEO Thomas J. Appio expressed disappointment but highlighted the drug’s safety profile.
- Analysts remain divided, with price targets recently adjusted between $8.00 and $12.00.
- Fourth-quarter and full-year 2025 financial results are scheduled for release on February 18, 2026.
What Happened to Bausch Health (BHC) Stock Today?
The 10.2% drop in BHC shares today stands in stark contrast to the broader specialty and generic drug manufacturing sector. While the industry average change was a modest decline of less than 1%, Bausch Health faced intense selling pressure.
Peer companies like Catalyst Pharmaceuticals (CPRX) and Jazz Pharmaceuticals (JAZZ) saw much smaller declines of around 2% and 1.4%, respectively.
| Company | Symbol | Daily Change |
|---|---|---|
| Catalyst Pharmaceuticals | CPRX | -1.98% |
| Jazz Pharmaceuticals | JAZZ | -1.39% |
| Indivior PLC | INDV | -1.43% |
| Industry Average | – | -0.97% |
| Bausch Health | BHC | -10.20% |
This downward movement continues a difficult trend for the company. Over the past year, Bausch Health shares have fallen more than 23%.
According to financial data, the stock is currently trading well below its 50-day moving average of C$9.57 and its 200-day moving average of C$9.38, signaling a bearish technical trend. Learning how to read stock charts can help investors better understand how these moving averages influence market momentum.
| Time Period | Price Change | Performance |
|---|---|---|
| 1 Month | -15.52% | 🔴 |
| 3 Months | -5.37% | 🔴 |
| 6 Months | -12.91% | 🔴 |
| 1 Year | -23.51% | 🔴 |
Did a Failed Clinical Trial Drive BHC's Decline, or is the Catalyst Unclear?
On January 23, 2026, Bausch Health announced that its RED-C Phase 3 clinical program did not achieve its primary endpoint. The trial was evaluating amorphous-rifaximin solid soluble dispersion (SSD) for the prevention of hepatic encephalopathy (HE) in adults with liver cirrhosis.
While the treatment was found to be safe and well-tolerated, it failed to show the necessary efficacy.
CEO Thomas J. Appio stated, “We are disappointed in the results, as there is currently no approved treatment for these patients.” Despite this clear clinical setback, some market analysis suggests the nearly 9% decline on the same day was not entirely explained by the trial results alone.
Analysts noted that the drop appeared to be part of a broader negative trend involving companies with meaningful debt.
What Are Analysts Saying About BHC's Future?
Wall Street remains cautious regarding Bausch Health’s outlook. Understanding how to find and interpret stock analyst ratings can help clarify the meaning of these updates.
On January 17, 2026, MarketBeat reported that financial analysis firm Wall Street Zen downgraded the stock to a “Buy” rating.
While this sounds positive, the downgrade reflects a moderation in sentiment from previous outlooks.
Other analysts have recently adjusted their expectations. JPMorgan analyst Chris Schott reiterated an “Overweight” rating but lowered the price target from $15.00 to $12.00.
Schott cited challenges in the Solta Medical segment and higher interest expenses as reasons for the reduction. Conversely, Truist Securities raised its price target from $7.00 to $8.00 earlier in January, suggesting some belief in the stock's underlying value.
Beyond RED-C: Key Company Developments and Upcoming Events
While the RED-C failure is a significant setback for the pipeline, investors are also focusing on the company's organizational shifts. A major point of interest is the pending spinoff of Solta Medical.
Analysts believe this move could unlock value, though the timeline and execution remain critical factors for the stock's recovery.
The company is also grappling with financial headwinds, including an earnings miss in a previous quarter where adjusted EPS of $0.85 fell short of the $0.92 consensus estimate. Investors are looking toward February 18, 2026, when Bausch Health will release its fourth-quarter and full-year 2025 results.
This report is expected to provide more clarity on the company's 2026 guidance and debt reduction progress.
How Does Bausch Health's Valuation Stand?
Despite the recent price collapse, some metrics suggest the stock may be undervalued relative to its historical norms. According to GuruFocus, the estimated “GF Value” for the stock is $8.90.
Based on the current price of $5.90, this would imply a potential upside of over 15% if the stock were to return to its estimated fair value. Tools like the best stock analysis apps often help investors cross-reference these valuation estimates against other pharmaceutical peers.
However, the consensus recommendation from seven analysts sits at a “Hold,” with an average one-year price target of $7.57. The company's P/E ratio currently stands at 8.41, reflecting the market's cautious stance on Bausch Health's growth prospects and its current debt load.
What Should BHC Investors Watch Next?
The immediate focus for investors will be the upcoming earnings call on February 18. Management is expected to address the next steps for the amorphous-rifaximin SSD compound, as CEO Appio mentioned the company is reviewing the full dataset to identify “potential new development opportunities.”
Investors should also monitor the performance of Bausch Health's core pharmaceutical business, which JPMorgan analysts described as stable. While the clinical failure and high interest expenses are clear bears cases, the safety profile of its pipeline candidates and the potential spinoff of Solta Medical provide a counter-narrative for those looking at the company's long-term restructuring efforts.
| 🟢 Bull Case | 🔴 Bear Case |
|---|---|
| • RED-C treatment safe and well-tolerated | • RED-C Phase 3 clinical trial failure |
| • GF Value upside estimated at 15.43% | • Significant debt load & interest expenses |
| • Core pharmaceutical business remains stable | • Underperforming sector significantly |
| • Potential value unlock from Solta spinoff | • Previous EPS miss ($0.85 vs $0.92) |
The Bottom Line
Bausch Health faces a challenging start to 2026, marked by a major clinical failure and a stock price that has dropped nearly 24% over the past year. While the core pharmaceutical business remains a foundation for the company, the lack of immediate pipeline catalysts and ongoing debt concerns continue to weigh on the valuation.
The upcoming February earnings report will be a pivotal moment for the company to regain investor trust. Until then, BHC remains a high-volatility stock as the market digests the implications of its failed HE trial and the timing of its next strategic business moves.
